ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients

After more than two decades in the clinic, Atara Biotherapeutics’ T cell therapy tabelecleucel is finally headed to the FDA — but not without a pivotal readout at this year’s ASH conference.

About half of patients responded to tab-cel, Atara’s candidate for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare complication that can occur after solid organ or hematopoietic stem cell transplant.